Ocuphire announced its phase II clinical trial poster was presented at the 83rd Scientific Sessions of the American Diabetes Association, titled “Oral APX3330 Reduces the DRSS Worsening after 24-weeks of Daily Treatment—Efficacy and Safety Results of the ZETA-1 Phase 2 Trial in Diabetic Retinopathy”. APX3330 is a first-in-class, small molecule oral drug, and is seeking to provide an alternative to intravitreal injection treatments. The clinical trial demonstrated that APS3330 reduced clinically meaningful progression of diabetic retinopathy (DR), as measured by the DR severity scale (DRSS).
Ocuphire is meeting with the FDA for its End of Phase 2 meeting to confirm the Phase 3 study design.